Skip to main content

Table 1 Baseline characteristics of the patients included in study group

From: RETRACTED ARTICLE: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B

Characteristic

Initial treatment of ETV-Brand

Age, years

61 (52.5–68.8)

Male sex, n (%)

119/175 (68.0%)

BMI, kg/m2

24.3 (22.2–27)

Period of ETV-Brand(years)

3.2 (2.7–4.3)

WBC, × 103/μL

5.8 (4.4–7.3)

HB, g/dL

13.8 (12.7–14.6)

Platelet, × 103/μL

145 (104–191)

ALT, U/L

24 (18–32)

AST, U/L

29 (24–36)

Total bilirubin, mg/dL

0.8 (0.6–1.1)

eGFR, mL/min/1.73 m2

81.8 (78.8–87.2)

FIB-4 score

2.7 (2.2–3.0)

HBeAg-positive, n (%)

34 (19.4%)

Detectable HBV DNA level, IU/mL

14.0 (12.4–16.5)

Undetectable HBV DNA, n (%)

142/175 (81%)

  1. Data are expressed as n (%) for categorical data and as mean ± standard deviation or median (interquartile range) for continuous data
  2. ETV-Brand, entecavir-brand drugs; BMI, body mass index; WBC, white blood cell; HB, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis-4; HBeAg, Hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid